Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) was upgraded by equities research analysts at Piper Sandler from a “neutral” rating to an “overweight” rating in a research report issued to clients and investors on Monday, Marketbeat Ratings reports. The firm currently has a $19.00 target price on the stock, up from their prior target price of $12.00. Piper Sandler’s price objective would indicate a potential upside of 58.20% from the company’s current price.
TEVA has been the subject of a number of other research reports. HSBC assumed coverage on Teva Pharmaceutical Industries in a research report on Monday, December 18th. They issued a “buy” rating and a $13.00 price objective for the company. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 1st. The Goldman Sachs Group increased their price objective on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a “neutral” rating in a report on Monday, February 5th. UBS Group upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and boosted their target price for the company from $11.00 to $13.00 in a report on Monday, November 27th. Finally, Barclays increased their price target on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average target price of $13.75.
Teva Pharmaceutical Industries Stock Down 0.7 %
Insider Buying and Selling
In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 31,766 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $12.37, for a total transaction of $392,945.42. Following the completion of the sale, the chief accounting officer now owns 10,676 shares in the company, valued at approximately $132,062.12. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.62% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the stock. Money Concepts Capital Corp bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $25,000. Quilter Plc acquired a new stake in Teva Pharmaceutical Industries during the first quarter valued at approximately $3,103,125,000. Tobam bought a new position in Teva Pharmaceutical Industries during the 2nd quarter worth approximately $25,000. Tower Research Capital LLC TRC grew its position in shares of Teva Pharmaceutical Industries by 1,729.5% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,787 shares of the company’s stock worth $39,000 after acquiring an additional 3,580 shares in the last quarter. Finally, US Bancorp DE increased its holdings in shares of Teva Pharmaceutical Industries by 36.5% in the 4th quarter. US Bancorp DE now owns 3,828 shares of the company’s stock valued at $40,000 after acquiring an additional 1,023 shares during the last quarter. 43.23% of the stock is owned by institutional investors and hedge funds.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.
- Five stocks we like better than Teva Pharmaceutical Industries
- How to Most Effectively Use the MarketBeat Earnings Screener
- Uber quadruples EPS estimates, but is growth decelerating?
- What is the S&P 500 and How It is Distinct from Other Indexes
- 3 stocks set to benefit from record Valentine’s Day spending
- Want to Profit on the Downtrend? Downtrends, Explained.
- Tradeweb is a disruptive pure play on financial market liquidity
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.